Table 1.

Characterization of the downregulation in splice correction activity induced by small molecule ligands.

Splice correction Inhibition ligands	IC50 (nM) ± SEM
CCG 203971 (CTGF inhibitor)	5020 ± 290
PF 573228 (focal adhesion kinase (FAK) inhibitor)	5670 ± 240
Atorvastatin LDL (HMG-CoA reductase inhibitor)	71 ± 0.25
Prostaglandin E2	651 ± 0.41

CCG 203971“N-(4-Chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidinecarboxamide”, PF 573228“ 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1 H)-quinolinone”, Atorvastatin LDL“(R,R)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt” and Prostaglandin E2“(5Z,11α,13E,15 S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1oic acid”.